About Ranbaxy Laboratories

ranbaxy.com

Ranbaxy Laboratories Limited, a pharmaceutical company, produces a range of generic medicines. The company has a presence in 49 countries, manufacturing facilities in 11 countries and serves customers in approximately 125 countries. Products The company manufactures and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates. Its product basket of approximately 5,000 SKUs available in approximately 125 countries worldwide, encompasses a therapeutic mix covering a majority of the chronic and acute segments. Research & Development The company offers value added formulations based on its Novel Drug Delivery System (NDDS) and New Chemical Entity (NCE) research outcomes. Novel Drug Delivery Systems (NDDS): The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations. In the oral NDDS space, Ranbaxy has developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. New Drug Discovery Research (NDDR): The company's NDDR program focuses on select therapeutic segments of Infectious diseases, Metabolic diseases, Inflammatory/ Respiratory disease and Oncology. The company has 8-10 programs in the area of NDDR. For Arterolane (potential Anti-malarial candidate), the company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials in India. The company is also profiling DPP-IV Inhibitors (Di-Peptidyl Peptidase IV Inhibitors) for Type-2-diabetes, a selective Phosphodiesterase 4-b inhibitor for COPD and Asthma, and a novel antibiotic antibacterial for Community Acquired Respiratory Tract Infection. Under an alliance with an academic institution in India, various medicinal plants are being evaluated as potential sources for novel pharmaceutical agents. The company also has collaborative research projects with other academic institutions in India in the area of Respiratory and Infectious disease. Significant Events In June 2008, Ranbaxy entered into an alliance with Daiichi Sankyo Company Ltd., to create a generic pharmaceutical powerhouse. On September 17, 2009, Ranbaxy Laboratories Ltd. has entered into a strategic in-licensing agreement for the Indian market with Medy-Tox Inc. for its cosmetic product, Neuronox. Neuronox is a botulinum toxin type A complex (100 Units) pharmaceutical manufactured by Medy-Tox. History Ranbaxy Laboratories Limited was founded in 1961.

Revenue : >1000M Industry : Pharmaceuticals Location : United States Employees : >10000

SaaS Adoption

SaaS Adoption indicates the level of adoption by this company of software as a service services.

Cloud Adoption

Cloud Adoption indicates the level of adoption by this company of cloud services.

IT Footprint

IT Footprint gives a relative indication of how much IT services this company consumes.

IT Spend

IT Spend shows roughly how much this client spends on IT per year in USD.

Enlyft tracks the use of over 15,000 technologies and has proprietary data on over 18 million companies worldwide.

Know the products your prospects use

Enlyft provides you with access to our real-time data platform where you can access insights into a company’s tech stack, firmographic data, and more.

Vendor Usage

Ranbaxy Laboratories uses 5 different technologies from 129 different vendors. They have above average use of several technologies including Java, Perl and Windows 10.

Product Categories

Ranbaxy Laboratories uses products from 93 different product categories. They are particularly heavy users of products in Database Management System, Business Intelligence, and Enterprise Resource Planning (ERP).

Recently Detected Technologies

Enlyft tracks the use of over 15,000 technologies and has proprietary data on over 18 million companies worldwide.

Technology Category Vendor Usage
Java Programming Languages Oracle
Perl Programming Languages Perl
Windows 10 Operating Systems Microsoft Corporation
Windows XP Operating Systems Microsoft Corporation
Worksoft Software Testing Tools Worksoft

Are you interested in knowing other companies with similar tech stacks?

Reveal what vendors your prospects are using

Enlyft Sales Insights gives you instant access to the tech stack and firmographics of millions of companies worldwide.
Logos provided by Clearbit

© Enlyft | All rights reserved.